PB1227 - Using the Hemophilia Functional Ability Scoring Tool (Hemo-FAST) to describe the joint health status in adults with hemophilia

Background: Despite increased availability of treatment options, a significant burden of joint disease remains in persons with hemophilia A (PwHA) and B (PwHB). The Hemophilia Functional Ability Scoring Tool (Hemo-FAST) is a newly developed quick and easy-to-use tool to evaluate joint status in clinical practice. A recent validation study of Hemo-FAST assessed the burden of disease using multiple tools (Barbay. Haemophilia 2023;29[S3]:17).

Aims: To describe the burden of disease in a population of PwHA and PwHB, including joint health, using data collected during the Hemo-FAST validation study*.

Methods: Between May 2021 and July 2022, adult PwHA and PwHB were recruited to French study sites to complete the Hemo-FAST patient-reported outcome and the short-form 36 health survey questionnaire. The Hemo-FAST clinician-reported outcome and the Haemophilia Joint Health Score (HJHS) were completed by clinicians. Demographics (gender, age, and body mass index) and medical history (disease severity, hemophilia type, treatment regimen, and joint bleeding episodes ≤12-months prior to enrolment) were also collected. Descriptive analyses by hemophilia type are presented.

Results: Of the 180 adults with hemophilia recruited to the study, 149 (82.8%) were PwHA and 31 (17.2%) were PwHB. The baseline demographics and characteristics were largely comparable between PwHA and PwHB (Table 1). The burden of disease in PwHA and PwHB was demonstrated by the mean (standard deviation) scores for Hemo-FAST of 26.0 (23.1) and 20.8 (22.4), HJHS of 14.4 (16.3) and 8.3 (12.3) and SF-36 physical component summary of 69.5 (20.0) and 74.2 (21.9), respectively (Table 2); severe hemophilia was associated with worse outcomes compared to non-severe hemophilia.

Conclusion(s): Despite advances in hemophilia treatment, the burden of disease of a representative European hemophilia population was demonstrated to be high in both PwHA and PwHB.
*NCT04731701, funded by Sobi